Plain-English translation of NCT07254585 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining two medications — SYS6010 and enlonstobart — can help treat head and neck squamous cell carcinoma that has come back or spread to other parts of the body. Researchers want to see if these medications work better together than one medication alone, and whether the side effects are manageable. The study will include about 70 patients across multiple hospitals.
Many people with advanced head and neck cancer cannot have surgery or traditional chemotherapy, and they need new treatment options. This trial is designed to see if this medication combination can help shrink tumors and improve survival for these patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive injections of the study medications on a 14-day cycle — meaning you get treatment, then have a 14-day break, then repeat. You will visit the hospital or clinic regularly for blood tests, scans, and check-ups to see how the treatment is working and to monitor for side effects. The trial is open-label, which means you and your doctor will know which medications you are receiving. Participation will continue as long as the treatment is helping and side effects remain acceptable.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China